Effect of switching from a combination therapy using DPP-4 inhibitor and insulin degludec to insulin degludec/liraglutide on blood glucose fluctuation in patients with type 2 diabetes
Not Applicable
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000039460
- Lead Sponsor
- Hokkaido University Hospital
- Brief Summary
Switching from DPP-4 inhibitor plus insulin degludec to IDegLira significantly improved MAGE from 74.9 (60.3, 97.7) mg/dL to 64.8 (52.0, 78.2) mg/dL (P < 0.05), as well as other indices of GV and 24-hour mean blood glucose concentration.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
1) History of anaphylaxis of insulin degludec or liraglutide 2) Unstable glycemic control 3) Severe hepatic dysfunction, renal dysfunction 4) Pregnancy 5) Diabetic ketosis, coma and precoma 6) Serious infection, pre-or post-surgery 7) Poor adherence to dietary therapy 8) Poor insulin secretion 9) Patients who thought to be inappropriate to enter this study for some reasons by physician's judgments
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method